Aurinia Pharmaceuticals Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for AUPH, updated each market day.
AUPH AI Sentiment
AI predicts Aurinia Pharmaceuticals Inc stock is likely to decrease over the next 10 market days.
Prediction date: July 2, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Sector
Exchange
Market Cap
$2,256,959,326
Cap Tier
Employees
128
Headquarters
EDMONTON, A0
Listed Since
Oct. 21, 2009
Website
AUPH Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AUPH Volatility
Aurinia Pharmaceuticals Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
